Article Text

Download PDFPDF

848 Impact of immunotherapy time-of-day infusion on overall survival in patients with metastatic renal cell carcinoma
  1. Jimmy Patel1,
  2. Amber Draper1,
  3. Yena Woo2,
  4. Layla Dhabaan2,
  5. Pretesh Patel1,
  6. Ashesh Jani1,
  7. Bradley Carthon1,
  8. Viraj Master1,
  9. Haydn Kissick1,
  10. Mehmet Bilen1,
  11. Zachary Buchwald1 and
  12. David Qian1
  1. 1Emory Winship Cancer Institute, Atlanta, GA, United States
  2. 2Emory University, Atlanta, GA, United States


Background Our prior study demonstrated that the time-of-day of immune checkpoint inhibitor (ICI) infusion influences clinical outcomes including overall survival (OS) for Stage IV melanoma patients. Similar results have subsequently been shown in lung cancer. In this study, we hypothesized that the time-of-day of ICI infusion may impact OS for patients with stage IV renal cell carcinoma (RCC).

Methods The treatment records of all patients with stage IV RCC who underwent ICI therapy within a multi-center academic hospital system between 2015 and 2020 were reviewed. Association between OS and proportion of ICI infusions received prior to 13:00 (cutoff to denote morning infusions) was evaluated using Cox proportional hazards regression.

Results In this study, there were 201 patients with stage IV RCC (28% female) who were administered ICIs and followed over a median of 18 months (IQR 5–30). Median age at the time of starting ICI treatment was 63 years (IQR 56–70). Initial ICI agents consisted of pembrolizumab (8%), nivolumab (61%), and dual nivolumab/ipilimumab (31%); table 1. The 119 patients (59%) who received at least a quarter of their ICI infusions in the morning had significantly longer OS (median 58 vs. 34 months, HR 0.51, 95% CI 0.29–0.89, P=0.017), independent of age, sex, RCC histology, liver and brain metastases, pre-treatment LDH, and choice of initial ICI; table 2, figure 1.

Conclusions Patients with metastatic RCC may benefit from earlier time-of-day ICI infusions. Our findings are consistent with established mechanisms of chrono-immunology, as well as with preceding analogous studies in melanoma and lung cancer. Additional prospective randomized trials are warranted.

Abstract 848 Table 1

Patient characteristics

Abstract 848 Table 2

Multivariable cox proportional hazards regression

Abstract 848 Figure 1

Kaplan-Meier overall survival

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.